moproc 40 mg enterosolventní tvrdé tobolky por cps etd 30x40mg - search results

prochlorperazine mesylate inj 5mg/ml liquid

sandoz canada incorporated - prochlorperazine (prochlorperazine mesylate) - liquid - 5mg - prochlorperazine (prochlorperazine mesylate) 5mg - phenothiazines

Australia - English - Department of Health (Therapeutic Goods Administration)

prochlorperazine gh prochlorperazine maleate 5 mg tablet blister pack

generic health pty ltd - prochlorperazine maleate, quantity: 5 mg - tablet - excipient ingredients: lactose monohydrate; maize starch; purified water; colloidal anhydrous silica; magnesium stearate - nausea and vomiting due to various causes including migraine; vertigo due to meniere's syndrome, labyrinthitis and other causes.

United States - English - NLM (National Library of Medicine)

prochlorperazine maleate tablet, film coated

a-s medication solutions - prochlorperazine maleate (unii: i1t8o1jtl6) (prochlorperazine - unii:yhp6ylt61t) - prochlorperazine 5 mg - prochlorperazine maleate tablets are indicated for the control of severe nausea and vomiting. prochlorperazine maleate tablets are also indicated for the treatment of schizophrenia. prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. however, prochlorperazine maleate tablets are not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). when used in the treatment of non-psychotic anxiety, prochlorperazine maleate tablets should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine maleate tablets at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings). the effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4-week clinical studies of outpatients with

United States - English - NLM (National Library of Medicine)

procainamide hydrochloride injection, solution

mckesson corporation - procainamide hydrochloride (unii: si4064o0lx) (procainamide - unii:l39wtc366d) - procainamide hydrochloride 100 mg in 1 ml - procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see warnings and boxed warning.) complete h